Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway

Abstract

HSCT in MS is an effective and relatively safe treatment option, with few serious complications and no mortality in Norway, so far. However, long-term adverse event with amenorrhea is a common problem.